GeneDx Holdings (WGS) Invested Capital (2020 - 2026)

GeneDx Holdings has disclosed Invested Capital across 7 years of filings, most recently posting $354.1 million for Q1 2026.

• In Q1 2026, Invested Capital rose 13.19% year-over-year to $354.1 million; the TTM figure through Mar 2026 stood at $354.1 million (up 13.19% YoY), while the FY2025 annual figure was $362.7 million, up 44.48% from the prior year.
• Invested Capital fell to $354.1 million in Q1 2026, from $362.7 million in the prior quarter.
• Over the last five years, Invested Capital for WGS reached as high as $648.3 million in Q2 2022 and fell as low as $234.3 million in Q4 2023.
• The 5-year median for Invested Capital is $312.9 million (2025), against an average of $334.6 million.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 214.69% — and 2023, when it tumbled 54.48%.
• A 5-year view of Invested Capital shows it stood at $260.0 million in 2022, then fell by 9.88% to $234.3 million in 2023, then climbed by 7.14% to $251.0 million in 2024, then surged by 44.48% to $362.7 million in 2025, then slipped by 2.37% to $354.1 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $354.1 million, $362.7 million, and $347.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.